Werewolf announces a merger with Ambros Therapeutics and secures $150M
The all-stock transaction rebrands the combined entity as Ambros Therapeutics and funds Phase 3 clinical trials for neridronate through 2029.
Latest Werewolf Therapeutics News & Updates
See the latest news and media coverage for Werewolf. We track all announcements, press releases, and industry mentions in real time, all in one place.
Last updated
Latest news about Werewolf Therapeutics (Werewolf)
In short: Werewolf agreed to merge with Ambros Therapeutics and secured $150 million in funding to advance neridronate through clinical trials.
Company announcements
Werewolf reports Q2 2026 financial results and updates
The company generated $3.7 million in net income after selling the JZP898 program to Jazz Pharmaceuticals for $21 million and repaying K2 HealthVentures debt.
Werewolf Therapeutics reports first quarter 2026 financial results
The firm sold JZP898 development rights to Jazz Pharmaceuticals, repaid its K2 loan, and maintains $46.5 million in cash amid a $13.5 million quarterly net loss.
Werewolf Therapeutics announces 2025 financial results and strategic review
The company holds $57.1 million in cash and hired Piper Sandler to evaluate potential mergers, asset sales, or licensing partnerships.
Media coverage
Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc. research and ratings by Barron's. View HOWL revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.
12 Health Care Stocks Moving In Friday s Pre-Market Session - Werewolf Therapeutics (NASDAQ:HOWL), Jupite
Gainers Werewolf Therapeutics (NASDAQ:HOWL) shares moved upwards by 74.6% to $0.75 during Friday's...
Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates
WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the "Company" or "Werewolf"), an innovative biopharmaceutical company pioneering the development of...
Never miss news about Werewolf
Track Werewolf and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Trending companies
Discover what's making headlines across other trending companies.
GlacierPoint
Bitmine
Osisko
DMAT
Temple
Pixelgen
Beam Global
Advance Auto Parts
Flux Power
Personalis
NAT
BioNTech
Zymeworks
YUNJI
Avidity Biosciences
Femasys
Forterra
8080.AI
Cardinal Infrastructure Group
Webull
Stitchflow
Hippolit
Gant Travel
SB Energy
Amex GBT
Navan
CTM
BCD Travel
Reed & Mackay
ATPI
EFR Travel
FCM
Perk
Nimbus Group
Omda